Pfizer’s Varenicline Smoking Cessation NDA Includes Comparison To Zyban
This article was originally published in Pharmaceutical Approvals Monthly
Pfizer’s prescription smoking cessation agent varenicline will have a user fee deadline in the first half of September 2006, assuming a standard 10-month review.
You may also be interested in...
The debate over analysis of clinical trial endpoints in FDA review documents for Pfizer’s Chantix (varenicline) provides a window into how the agency’s view of smoking cessation trial design is changing as new therapeutic classes emerge.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011